Dr. Horwitz is currently Professor and Co-chair of the Department of Molecular Pharmacology at the Albert Einstein College of Medicine of Yeshiva University.

An associate director of the Albert Einstein Comprehensive Cancer Center, Dr. Horwitz is also the Rose C. Falkenstein Professor of Cancer Research at Einstein. She is widely recognized for her fundamental findings about mechanisms by which Taxol inhibits cell growth. Her research led to its development, and eventual approval, as a treatment for ovarian, breast and lung cancers. The characteristics of Taxol that have distinguished it from other cancer chemotherpeutic agents are its novel chemical structure, its unique mechanism of action in blocking cell division and its activity in solid tumors. Her recent work is related to the development of new drugs that will be effective in Taxol-resistant human tumors.

Dr. Horwitz received a 1972 Research Starter Grant in Pharmacology/Toxicology.